Belantamab mafodotin is the first drug-conjugated antibody (ADC) used for MM treatment and it targets B-cell maturation antigen (BCMA)-expressing myeloma cells [47]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.